

## Special Issue

# Small Extracellular Vesicles: A Novel Avenue for Brain Tumor Management

### Message from the Guest Editors

It is quite ascertained that extracellular vesicles (EVs) mediate cell-to-cell communication in cancer. In the brain, EVs are secreted by not only tumor cells, but also all the other existing cell types. Recent studies reveal that miRNAs are secreted in the body fluids as EV cargo and are able to influence the recipient cell phenotype, miRNA contained in EVs are promising candidate liquid biomarkers of great significance for cancer. In this scenario, the isolation of miRNAs from EVs to identify molecular signatures for brain tumor early diagnosis could possibly replace the more costly and invasive tissue biopsy procedures in the near future. The purpose of this Special Issue is to attract articles (both original research articles and reviews) from experts in the field of EV research in the brain tumor that can take innovative approaches or express novel views on the multifaceted world of EVs in cancer biology, progression and therapy.

---

### Guest Editors

Dr. Igea D'Agnano

Institute for Biomedical Technologies (ITB), National Research Council (CNR), Segrate, Milan, Italy

Dr. Ingrid Cifola

Institute for Biomedical Technologies (ITB), National Research Council (CNR), Segrate, Milan, Italy

---

### Deadline for manuscript submissions

closed (30 June 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/82875](https://mdpi.com/si/82875)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).